A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts

David R Gandara, C. A. Ries, S. A. Schiff, C. B. George, J. P. Lewis, M. M. Koretz, S. K. Carter

Research output: Contribution to journalArticle

Abstract

Prednimustine, an ester of chlorambucil and prednisolone, was evaluated for efficacy and toxicity in a selected group of leukemia patients with a poor prognosis. Disease subsets consisted of patients with acute non-lymphocytic leukemia (ANLL) over age 60; ANLL refractory to standard therapy; smouldering leukemia; and refractory anemia with excess blasts (RAEB). In agreement with previous studies, toxicity from Prednimustine was relatively mild, consisting primarily of infrequent myelosuppression, gastrointestinal side-effects, and mild hyperglycemia. This study did not, however, confirm previously reported remission rates in ANLL: in 41 evaluable patients only two complete remissions were achieved. Both occurred in the subset of patients with smouldering leukemia. We conclude that Prednimustine has limited activity in this patient population.

Original languageEnglish (US)
Pages (from-to)10-12
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume9
Issue number1
DOIs
StatePublished - Sep 1982
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this